Statement from David Brandling Bennett, Bill & Melinda Gates Foundation and Bernard Nahlen, U.S Presidents Malaria Initiative; Co-Chairs of the GMAP2 Task Force: "After months of extensive enquiry and a world-wide consultation which targeted constituencies and stakeholders in all sectors of society, we are delighted to invite the broader development community to review the penultimate … [Read more...]
G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries
Primaquine is a key drug for malaria elimination. In addition to being the only drug active against the dormant relapsing forms of Plasmodium vivax, primaquine is the sole effective treatment of infectious P. falciparum gametocytes, and may interrupt transmission and help contain the spread of artemisinin resistance. However, primaquine can trigger haemolysis in patients with a deficiency in … [Read more...]
EDITORIAL – Reflections on World Malaria Day 2011
How far have we come in the last four years? Four years ago, it was estimated that a child died every 30 seconds from malaria, and that more than a million people each year were killed by this devastating and debilitating disease. Four years ago, the malaria advocacy partnership Roll Back Malaria organized the first World Malaria Day, and published the Global Malaria Action Plan (GMAP), which … [Read more...]
Urgent Action Essential to Protect Malaria Therapies, Says WHO
The world risks losing its most potent treatment for malaria unless steps are quickly taken to prevent the development and spread of drug resistant parasites, according to a new action plan released today by WHO and Roll Back Malaria partnership (RBM). The Global plan for artemisinin resistance containment outlines the necessary actions to contain and prevent resistance to artemisinins, … [Read more...]